Summary The Top 10 Generic Pharmaceutical Companies of 2025 highlight the continued growth and resilience of the global generics industry, led by Sandoz, Sun Pharma, and Fosun Pharma....
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: CORONA Remedies is using the Wokadine acquisition to buy its way into India’s ₹648 crore povidone-iodine market with a #2-ranked, 46‑year-old antise...
Key Highlights: Implications: Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly i...
Key Highlights: Implications: Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...
